Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs

NCT06726720 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06726720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06726720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
December 16, 2024
Completion date
June 30, 2032
Enrollment
300 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

real world multi-cohort study of patients with non-small cell lung cancer (nsclc) initiating approved drugs developed by az or as part of an az alliance